Literature DB >> 21907096

Experimental models of HD and reflection on therapeutic strategies.

Jinho Kim1, Olivia L Bordiuk, Robert J Ferrante.   

Abstract

Huntington's disease (HD) is an autosomal dominant, progressive, and fatal neurodegenerative disorder caused by an expanded polyglutamine cytosine-adenine-guanine repeat in the gene coding for the protein huntingtin. Despite great progress over the past two decades since the identification of the gene mutation, a direct causative pathway from the HD gene mutation to neuronal dysfunction and death has not yet been established. One important advance in understanding the pathogenic mechanisms of this disease has been the development of experimental mouse models that replicate many of the clinical, neuropathological, and molecular events in HD patients. These murine models have played a critical role in providing accurate and experimentally accessible systems to study multiple features of disease pathogenesis and to test potential therapeutic strategies. A better understanding of the pathophysiological mechanisms of disease and how they interrelate has become important in identifying a treatment for HD and in the design of human clinical trials. In this chapter, we review the current state of HD mouse models and their successes in elucidating disease pathogenesis and in developing pharmacotherapies. There is no clinically proven treatment for HD that can halt or ameliorate the inexorable disease progression. As such, a guide to assessing studies in mouse models and salient issues related to translation from mice to humans are included.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907096     DOI: 10.1016/B978-0-12-381328-2.00016-X

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  8 in total

1.  Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction.

Authors:  Verónica Brito; Albert Giralt; Lilian Enriquez-Barreto; Mar Puigdellívol; Nuria Suelves; Alfonsa Zamora-Moratalla; Jesús J Ballesteros; Eduardo D Martín; Nuria Dominguez-Iturza; Miguel Morales; Jordi Alberch; Sílvia Ginés
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

2.  Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.

Authors:  Bronwen Martin; Wayne Chadwick; Wei-na Cong; Nick Pantaleo; Caitlin M Daimon; Erin J Golden; Kevin G Becker; William H Wood; Olga D Carlson; Josephine M Egan; Stuart Maudsley
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

3.  Regulation of BDNF Release by ARMS/Kidins220 through Modulation of Synaptotagmin-IV Levels.

Authors:  Saray López-Benito; Julia Sánchez-Sánchez; Verónica Brito; Laura Calvo; Silvia Lisa; María Torres-Valle; Mary E Palko; Cristina Vicente-García; Seila Fernández-Fernández; Juan P Bolaños; Silvia Ginés; Lino Tessarollo; Juan C Arévalo
Journal:  J Neurosci       Date:  2018-05-16       Impact factor: 6.167

4.  A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's disease.

Authors:  Mar Puigdellívol; Marta Cherubini; Verónica Brito; Albert Giralt; Núria Suelves; Jesús Ballesteros; Alfonsa Zamora-Moratalla; Eduardo D Martín; Betty A Eipper; Jordi Alberch; Silvia Ginés
Journal:  Hum Mol Genet       Date:  2015-10-12       Impact factor: 6.150

Review 5.  Role of cerebral cortex in the neuropathology of Huntington's disease.

Authors:  Ana M Estrada-Sánchez; George V Rebec
Journal:  Front Neural Circuits       Date:  2013-02-18       Impact factor: 3.492

Review 6.  Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.

Authors:  Renbao Chang; Xudong Liu; Shihua Li; Xiao-Jiang Li
Journal:  Drug Des Devel Ther       Date:  2015-04-15       Impact factor: 4.162

7.  Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.

Authors:  Andreas Weiss; Ulrike Träger; Edward J Wild; Stephan Grueninger; Ruth Farmer; Christian Landles; Rachael I Scahill; Nayana Lahiri; Salman Haider; Douglas Macdonald; Chris Frost; Gillian P Bates; Graeme Bilbe; Rainer Kuhn; Ralph Andre; Sarah J Tabrizi
Journal:  J Clin Invest       Date:  2012-09-17       Impact factor: 14.808

8.  Synaptic RTP801 contributes to motor-learning dysfunction in Huntington's disease.

Authors:  Núria Martín-Flores; Leticia Pérez-Sisqués; Jordi Creus-Muncunill; Mercè Masana; Sílvia Ginés; Jordi Alberch; Esther Pérez-Navarro; Cristina Malagelada
Journal:  Cell Death Dis       Date:  2020-07-30       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.